AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?

Per CNBC, AstraZeneca's premium stock valuation is facing tough questions after a trial setback. The European pharmaceutical giant has commanded a rich share price based on the strength of its drug pipeline.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton